Ipsen : Confident but cautious tone – Forecasts and target price revised up
>Main elements: news flow still positive - We note the following items in particular:1- The fall in Q2 sales of Decapeptyl® (15% of sales), Dysport® (13%) and OTC seem to clearly come from the impact of COVID-19 and lockdown (fewer consultations and closure of medical centres). Ipsen notes a slow improvement since June-July, even if China seems to be resuming fairly slowly in relation to Europe.Moreover, while the diagnosis of NET new patients has decreased,...Ipsen is global biotechnology specialty care company. Co. engages in research, development, manufacture and sale of pharmaceutical products for human healthcare. Co.'s product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology and haematology). These products are specialist care drugs. Co. also markets products in other therapeutic areas including gastroenterology, cardiovascular and cognitive disorders. These products are primary care drugs. Co.'s brand names include Decapeptyl®, Somatuline®, Dysport®, Nutropin Aq®, Smecta®, Forlax®, Nisis®,Adrovance®, Exforge® and Adenuric®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.